Drug Interactions between st. john's wort and Trileptal
This report displays the potential drug interactions for the following 2 drugs:
- st. john's wort
- Trileptal (oxcarbazepine)
Interactions between your drugs
St. John's wort OXcarbazepine
Applies to: st. john's wort and Trileptal (oxcarbazepine)
MONITOR: Coadministration with potent CYP450 inducers may decrease the plasma concentrations of the pharmacologically active 10-monohydroxy metabolite of oxcarbazepine known as MHD. Administration of oxcarbazepine 900 mg/day in combination with carbamazepine 400 to 2000 mg/day has resulted in an average reduction of MHD plasma concentrations by approximately 40%. Phenytoin 250 to 500 mg/day and phenobarbital 100 to 150 mg/day have reduced the plasma concentrations of MHD on average by approximately 30% and 25%, respectively, when oxcarbazepine was coadministered at 600 to 1800 mg/day. Since MHD is responsible for much of the pharmacologic effects of oxcarbazepine, the potential for altered anticonvulsant activity should be considered. Oxcarbazepine had no significant effect on the pharmacokinetics of carbamazepine and phenobarbital, but increased the plasma concentrations of phenytoin by 40% when administered at dosages greater than 1200 mg/day.
MANAGEMENT: The possibility of diminished therapeutic effects of oxcarbazepine should be considered when used in combination with potent CYP450 inducers such as carbamazepine, phenobarbital, phenytoin, primidone (which is metabolized to phenobarbital), rifampin, and St. John's wort. Close clinical and laboratory monitoring is recommended whenever a CYP450 inducer is added to or withdrawn from oxcarbazepine therapy, and the dosage adjusted as necessary.
References (1)
- (2001) "Product Information. Trileptal (oxcarbazepine)." Novartis Pharmaceuticals
Drug and food interactions
St. John's wort food
Applies to: st. john's wort
GENERALLY AVOID: An isolated case report suggests that foods containing large amounts of tyramine may precipitate a hypertensive crisis in patients treated with St. John's wort. The mechanism of interaction is unknown, as St. John's wort is not thought to possess monoamine oxidase (MAO) inhibiting activity at concentrations achieved in vivo. The case patient was a 41-year-old man who had been taking St. John's wort for seven days prior to presentation at the emergency room with confusion and disorientation. The patient recalled last eating aged cheese and having a glass of red wine approximately 10 hours prior to admission. No other cause of delirium or hypertension could be identified. In addition, alcohol may potentiate some of the pharmacologic effects of St. John's wort. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Until further information is available, patients treated with St. John's wort should consider avoiding consumption of protein foods in which aging or breakdown of protein is used to increase flavor. These foods include cheese (particularly strong, aged or processed cheeses), sour cream, wine (particularly red wine), champagne, beer, pickled herring, anchovies, caviar, shrimp paste, liver (particularly chicken liver), dry sausage, figs, raisins, bananas, avocados, chocolate, soy sauce, bean curd, yogurt, papaya products, meat tenderizers, fava beans, protein extracts, and dietary supplements. Caffeine may also precipitate hypertensive crisis so its intake should be minimized as well. Patients should also be advised to avoid or limit consumption of alcohol.
References (1)
- Patel S, Robinson R, Burk M (2002) "Hypertensive crisis associated with St. John's Wort." Am J Med, 112, p. 507-8
OXcarbazepine food
Applies to: Trileptal (oxcarbazepine)
GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (4)
- Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
- Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
- (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
- (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.